TELOMIR PHARMACEUTICALS INC (TELO)
US87975F1049 - Common Stock
Top movers in Friday's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
Telomir Pharmaceuticals (NASDAQ: TELO), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, will be spotlighted during the upcoming episode of “Health Uncensored with Dr. Drew.” The show will be broadcast on Fox Business Network at 5:30 p.m. EST on Sept. 29, 2024. Dr. Drew will talk […]
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024
Telomir Pharmaceuticals just reported results for the second quarter of 2024.
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Telomir Pharmaceuticals (NASDAQ:TELO) just reported results for the second quar...
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions ...
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage...
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and...
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the...
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024
Telomir Pharmaceuticals just reported results for the first quarter of 2024.
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Telomir Pharmaceuticals (NASDAQ:TELO) just reported results for the first quart...
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic...
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by...
UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to...
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to...
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal...
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science
Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditions...
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
Together with its partner, Frontage Laboratories, Telomir’s poster focused on pre-clinical data demonstrating Telomir-1’s ability to elongate telomere caps...
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related...
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage...
Telomir Pharmaceuticals stock falls 29% following $7M IPO (NASDAQ:TELO)
Telomir Pharmaceuticals (TELO) shares were down nearly 30% in early afternoon trading Friday following the drug developer’s $7M initial public offering. Shares
Telomir Pharmaceuticals files for proposed $14M IPO (TELO)
Telomir Pharmaceuticals (TELO) files for $14M IPO, seeking to list its shares on Nasdaq under symbol TELO. Read more here.